Beta-Agonists Flashcards
Salmeterol
Sympathomimetic, Adrenergic, β2-agonist
Serevent Diskus (β2)-DPI
LABA
Onset: 20 min; Peak: 3-5 hrs; Duration: 12 hours
Albuterol (5)
Sympathomimetic, Adrenergic, β2-agonist, Saligenin
Proventil, Proair, Accuneb, VoSpire ER (β2) - SVN, MDI, TAB, Syrup
SABA
(VoSpire ER = extended release)
Onset: 15 min; Peak: 30-60 min; Duration 5-8 hrs
Arformoterol
Sympathomimetic, Adrenergic, β2-agonist
Brovana (β2) - SVN
LABA
Onset: 15 min; Peak: 30-60 min; Duration: 12 hr
Isoetharine
Sympathomimetic, Adrenerguc, β2 agonist, Catecholamine
Bronkosol (β2)
Pirbuterol
Sympathomimetic, Adrenergic, β2-agonist
Maxair Autohaler (β2) - MDI
SABA
Onset: 5 min; Peak: 30 min; Duration 5 hr
Metaproteranol
Sympathomimetic, Adrenergic, β2-agonist, Resorcinol
Alupent (β2) - SVN, TAB, Syrup
SABA
Onset: 1-5 min; Peak: 60 min; Duration 2-6 hr
Racemic Epinephrine
Sympathomimetic, Adrenergic, β2-agonist, Catecholamine
Micronefrin (α, β) - SVN
Ultra SABA
Onset: 3-5 min; Peak: 5-20 min; Duration: 0.5-2 hr
Isoproterenol
Sympathomimetic, Adrenergic, β2-agonist, Catecholamine
Isuprel (β1 & β2)
Not available through nebulizer solution, available parenterally
Vilanterol
Sympathomimetic, Adrenergic, β2-agonist
LABA
Only approved in the U.S. in combination w/ fluticasone furoate as BREO ELLIPTA
Indacaterol
Sympathomimetic, Adrenergic, β2-agonist
Arcapta Neohaler
LABA
Epinephrine
Sympathomimetic, Adrenergic, β2-agonist, Catecholamine
Adrenaline chloride, Primatene Mist (α, β) - SVN, MDI
Ultra SABA
Onset: 3-5 min; Peak: 5-20 min; Duration: 1-3 hr
Fomoterol (3)
Sympathomimetic, Adrenergic, β2-agonist
Foradil, Centihaler, Perforomist (β2) - SVN, DPI
LABA
Onset: 15 min; Peak: 30-60 min; Duration: 12 hr
Bitolterol
Sympathomimetic, Adrenergic, β2-agonist
Tornalate
Removed from the market
Prodrug
Levalbuterol
Sympathomimetic, Adrenergic, β2-agonist Xopenex (β2) - SVN, MDI SABA Only has the (R)-isomer Onset: 15 min; Peak: 30-60 min; Duration: 5-8 hr
KT: Adrenergic Bronchodilator
agent that stimulates sympathetic nervous fibers, which allow relaxation of smooth muscle in the airway. aka sympathomimetic bronchodilator or β2-agonist
KT: α-receptor stimulation
causes vasoconstriction and vasopressor effect; in the upper airway, this can provide decongestion
KT: asthma paradox
the increasing incidence of asthma morbidity, and esp. asthma mortality, despite advances in the understanding of asthma and availability of improved drugs to treat asthma
KT: β1-receptor stimulation
causes increased myocardial conductivity and increased heart rate as well as increased contractile force
KT: β2-receptor stimulation
causes relaxation of bronchial smooth muscle, with some inhibition of inflammatory mediator release and stimulation of mucociliary clearance
KT: bronchospasm
narrowing of the bronchial airways, caused by contraction of smooth muscle
KT: catecholamines
group of similar compounds having sympathomimetic action, they mimic the actions of epinephrines
KT: downregulation
nucleotide produced by long-term desensitization of β receptors to β2-agonists, caused by a reduction in the number of β receptors
KT: prodrug
drug that exhibits its pharmacologic activity when it is converted, inside the body, to its active form
KT: sympathomimetic
producing effects similar to those of the sympathetic nervous system
β-adrenergic can effect V/Q ratio
Leads to a decreased PaO2 and increase in PaCO2